5 Key Sessions and Interviews at ASCO 2022 Annual Meeting

Pharmacy Times will be covering the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting live in Chicago, Illinois, from June 3 through 7, 2022.

Pharmacy Times will be covering the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting live in Chicago, Illinois, from June 3 through 7, 2022.

This year’s program will include presentations on new research in cancer care, with more than 200 sessions around the theme “Advancing Equitable Cancer Care Through Innovation.” The meeting also features abstracts in more than 120 subcategories including all major disease sites and research areas.

Stay tuned on PharmacyTimes.com for exclusive session coverage and interviews with experts, including:

  • A conversation with Kelly McAuliff, PharmD, BCOP, CSP, about research on the impact of COVID-19 on oral oncolytic adherence among patients with ovarian or prostate cancer, or chronic myelogenous leukemia. The researchers also examined the role of digital engagement in mitigating these impacts on adherence.
  • In a session on June 4, experts will discuss the safety and efficacy of venetoclax in combination with azacytidine or decitabine for patients with untreated acute myeloid leukemia in an outpatient setting.
  • In an interview with Pharmacy Times, researcher and oncologist Bradley Monk, MD, FACOG, FACS, will discuss new results from the ATHENA-MONO trial investigating the use of rucaparib in ovarian cancer. The trial is investigating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in patients with ovarian cancer.
  • In a session on June 6, researchers will discuss the use of alpelisib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutated advanced breast cancer. New data being presented include a baseline biomarker analysis and progression-free survival findings by duration of prior cyclin-dependent kinase 4/6 inhibitor therapy in the BYLieve study.
  • In a conversation with Pharmacy Times, Stephen Ansell, MD, PhD, will discuss the ECHELON-1 trial and new data being presented at ASCO 2022. The trial is investigating brentuximab vedotin and its use in Hodgkin lymphoma.

Stay tuned on PharmacyTimes.com and follow Pharmacy Times on social media for exclusive, live coverage and the latest updates from the ASCO 2022 Annual Meeting.